Prevalence of CIN2+, and performance of screening tests singly or in combination by CD4+ count among HIV-positive women in Burkina Faso and South Africa
| CD4 < 200 cells/µL | CD4 200–349 cells/µL | CD4 ≥ 350 cells/µL | P-value for trend | |
|---|---|---|---|---|
| CIN2+ prevalence | ||||
| Burkina Faso(N = 511 evaluated women) | 7/54 (13%) | 4/102 (4%) | 19/355 (5%) | P = 0.09 |
| South Africa(N = 438 evaluated women) | 21/44 (48%) | 35/101 (35%) | 69/293 (24%) | P < 0.001 |
| Sensitivity to detect CIN2+ (N = 155) | ||||
| HR-HPV | 100% | 94% | 85% | P = 0.07 |
| Cytology (LSIL) | 92% | 94% | 94% | P = 0.81 |
| Cytology (HSIL) | 80% | 72% | 57% | P = 0.03 |
| VIA/VILI | 68% | 64% | 58% | P = 0.32 |
| HPV + Cytology | 100% | 100% | 98% | P = 1.00 |
| HPV + VIA/VILI | 100% | 100% | 93% | P = 1.00 |
| Cytology + VIA/VILI | 96% | 97% | 96% | P = 0.99 |
| Specificity to detect CIN2+ (N = 155) | ||||
| HR-HPV | 36% | 47% | 63% | P < 0.001 |
| Cytology (LSIL) | 49% | 50% | 56% | P = 0.13 |
| Cytology (HSIL) | 87% | 90% | 91% | P = 0.30 |
| VIA/VILI | 77% | 74% | 74% | P = 0.72 |
| HPV + Cytology (HSIL) | 29% | 32% | 41% | P = 0.02 |
| HPV + VIA/VILI | 30% | 38% | 49% | P = 0.002 |
| Cytology (HSIL) + VIA/VILI | 42% | 42% | 47% | P = 0.28 |